fda

Ignite It
3 min read • March 6, 2019

Gottlieb’s Departure Creates Uncertainty For Tobacco, Biopharma, Cannabis Industries

Ignite It
2 min read • December 24, 2018

FDA: CBD Products Mostly Illegal

Ignite It
3 min read • December 21, 2018

FDA Warms To Considering Legal Cannabis Ingredients In Food

Ignite It
1 min read • December 20, 2018

FDA’s Gottlieb Says Will Advance New Steps To Better Define FDA’s Public Health Obligations In Area Of Cannabis

Ignite It
6 min read • December 20, 2018

The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Ignite It
2 min read • October 2, 2018

Pyxus’ Indirect Canadian Subsidiary Receives ACMPR Cannabis Cultivation License From Health Canada

Ignite It
1 min read • September 24, 2018

Governor Cuomo Adds Pain Management To Medical Marijuana Treatment

Ignite It
1 min read • September 19, 2018

Cannabinoid Biotech Stocks Higher After Morgan Stanley Earlier Said the U.S. DEA Is Expected This Week To Reclassify GW Pharma’s CBD Epidiolex For Medicinal Use; GW Pharma Shares Up 5.8%, Peer Zynerba Pharma Shares Up 5.1%

Ignite It
1 min read • September 4, 2018

INSYS Therapeutics And UC San Diego’s Center For Medicinal Cannabis Research Expand Collaboration To Include Clinical Study Of Cannabidiol In Early Psychosis

Ignite It
1 min read • July 12, 2018

GW Pharmaceuticals Down 3% Premarket After Zogenix Announces Positive Outcome Of ZX008 Trial; ZX008 Is Rival To GW’s Epidiolex, A Cannabis-Based Seizure Treatment

Ignite It
1 min read • July 5, 2018

Zynerba Pharmaceuticals Says Phase 1 Study Indicates that Target Blood Levels Of 5-15 Ng/ml THC Were Not Achieved

Ignite It
15 min read • June 29, 2018

Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Browse By Channels

 After-Hours Center
 Analyst Color
 Analyst Ratings
 Andy Barr
 Asia
 Asset Sales
 Be Your Own Boss
 Binary Options
 Biotech
 Bonds
 Broad U.S. Equity ETFs
 Buybacks
 california cannabis
 Cannabis
 cannabis earnings
 cannabis farms
 cannabis study
 Christopher Dillis
 CNBC
 Commodities
 Congress cannabis
 Congress hemp
 Contracts
 Crowdsourcing
 Cryptocurrency
 Currency ETFs
 Dividends
 Downgrades
 Earnings
 Earnings Beats
 Earnings Misses
 Econ #s
 Economics
 Education
 Emerging Market ETFs
 Emerging Markets
 Entertainment
 Entrepreneurship
 Equities
 ESG
 ETFs
 Eurozone
 Events
 Exclusives
 Fast Money
 FDA
 Federal Reserve
 Financial Advisors
 Financing
 Fintech
 first quarter earnings
 Forex
 Futures
 Gaming
 General
 Global
 Government
 Guidance
 Health Care
 Hedge Funds
 hemp bill
 hemp legalization
 hemp regulation
 Hot
 illegal cannabis farms
 Initiation
 Insider Trades
 Insurance
 Interview
 intoxicating hemp-derived products
 Intraday Update
 IPOs
 James Comer
 Large Cap
 Latin America
 Legal
 Long Ideas
 M&A
 Macro Economic Events
 Macro Notification
 Management
 marijuana
 Market Summary
 Market-Moving Exclusives
 Markets
 Media
 Mid Cap
 Movers
 Movers & Shakers
 New ETFs
 News
 Offerings
 Opinion
 Options
 Penny Stocks
 Personal Finance
 Politics
 Pre-Market Outlook
 Press Releases
 Previews
 Price Target
 Psychedelics
 Psychology
 Real Estate
 Regulations
 REIT
 Reiteration
 Rescheduling
 Restaurants
 Retail Sales
 Reviews
 Rumors
 SEC
 Sector ETFs
 Short Ideas
 Short Sellers
 Signals
 Small Business
 Small Cap
 Small Cap Analysis
 Social Media
 Specialty ETFs
 Sports
 Sports Betting
 Startups
 Stock Split
 Success Stories
 Taxes
 Tech
 Technicals
 THC
 Top Stories
 Topics
 Trading Ideas
 Travel
 UC Berkeley Cannabis Research Center
 unlicensed cannabis
 Upgrades
 WIIM

Join the Cannabis Revolution

Ready to access the most aggressive cannabis intelligence platform? Get started with IGNITE IT today.